Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control.

Epidemic control strategies alter the spread of the disease in the host population. In this paper, we describe and discuss mathematical models that can be used to explore the potential of pre-exposure and post-exposure vaccines currently under development in the control of tuberculosis. A model with bacille Calmette-Guerin (BCG) vaccination for the susceptibles and treatment for the infectives is first presented. The epidemic thresholds known as the basic reproduction numbers and equilibria for the models are determined and stabilities are investigated. The reproduction numbers for the models are compared to assess the impact of the vaccines currently under development. The centre manifold theory is used to show the existence of backward bifurcation when the associated reproduction number is less than unity and that the unique endemic equilibrium is locally asymptotically stable when the associated reproduction number is greater than unity. From the study we conclude that the pre-exposure vaccine currently under development coupled with chemoprophylaxis for the latently infected and treatment of infectives is more effective when compared to the post-exposure vaccine currently under development for the latently infected coupled with treatment of the infectives.

[1]  C. Bhunu,et al.  Tuberculosis Transmission Model with Chemoprophylaxis and Treatment , 2008, Bulletin of mathematical biology.

[2]  U. Fruth,et al.  Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  Elamin H Elbasha,et al.  Theoretical Assessment of Public Health Impact of Imperfect Prophylactic HIV-1 Vaccines with Therapeutic Benefits , 2006, Bulletin of mathematical biology.

[4]  J. Deeks,et al.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak , 2003, The Lancet.

[5]  Carlos Castillo-Chavez,et al.  Dynamical models of tuberculosis and their applications. , 2004, Mathematical biosciences and engineering : MBE.

[6]  Herbert W. Hethcote,et al.  The Mathematics of Infectious Diseases , 2000, SIAM Rev..

[7]  J. Watmough,et al.  Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. , 2002, Mathematical biosciences.

[8]  E. Ziv,et al.  Potential Public Health Impact of New Tuberculosis Vaccines , 2004, Emerging infectious diseases.

[9]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[10]  P. Andersen.  Vaccine strategies against latent tuberculosis infection. , 2007, Trends in microbiology.

[11]  M. Iseman.  A Clinician's Guide to Tuberculosis , 2000 .

[12]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[13]  C. Franco-Paredes,et al.  The ever-expanding clinical spectrum of tuberculosis. , 2002, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[14]  J. Sadoff,et al.  Advances in tuberculosis vaccine strategies , 2006, Nature Reviews Microbiology.

[15]  B G Williams,et al.  Criteria for the control of drug-resistant tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Marion Muehlen,et al.  Implications of partial immunity on the prospects for tuberculosis control by post-exposure interventions. , 2007, Journal of theoretical biology.

[17]  P. Fine,et al.  The BCG Experience: Implications for Future Vaccines against Tuberculosis , 1994 .

[18]  C. Franco-Paredes,et al.  Infectious Diseases, Non–Zero‐Sum Thinking, and the Developing World , 2003, The American journal of the medical sciences.

[19]  G. Rook,et al.  Progress and hindrances in tuberculosis vaccine development , 2006, The Lancet.

[20]  S M Blower,et al.  Potential impact of tuberculosis vaccines as epidemic control agents. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Christopher Dye,et al.  Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .

[22]  C. F. von Reyn,et al.  New vaccines for the prevention of tuberculosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  P. Andersen,et al.  Vaccines for Tuberculosis: Novel Concepts and Recent Progress , 2005, Clinical Microbiology Reviews.

[24]  B. Bloom,et al.  Tuberculosis Pathogenesis, Protection, and Control , 1994 .

[25]  R. Huebner,et al.  The tuberculin skin test. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Elsie Lee,et al.  Evolution and current use of the tuberculin test. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  S. Kaufmann,et al.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.

[28]  James O Lloyd-Smith,et al.  Prospects for Advancing Tuberculosis Control Efforts through Novel Therapies , 2006, PLoS medicine.

[29]  C. Dye,et al.  The Development and Impact of Tuberculosis Vaccines , 2006, Cell.

[30]  M. Behr.  BCG--different strains, different vaccines? , 2002, The Lancet. Infectious diseases.

[31]  M. Horwitz.  Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. , 2005, Microbes and infection.

[32]  G. Hussey,et al.  Childhood tuberculosis: old and new vaccines. , 2007, Paediatric respiratory reviews.

[33]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[34]  Ci-yong Lu,et al.  Treatment outcome of new pulmonary tuberculosis in Guangzhou, China 1993–2002: a register-based cohort study , 2007, BMC public health.